Free Trial
NASDAQ:BBIO

BridgeBio Pharma (BBIO) Stock Price, News & Analysis

BridgeBio Pharma logo
$23.04 +0.50 (+2.22%)
(As of 11/20/2024 ET)

About BridgeBio Pharma Stock (NASDAQ:BBIO)

Key Stats

Today's Range
$22.05
$23.16
50-Day Range
$22.35
$27.09
52-Week Range
$21.62
$44.32
Volume
1.40 million shs
Average Volume
1.85 million shs
Market Capitalization
$4.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.57
Consensus Rating
Moderate Buy

Company Overview

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
92nd Percentile Overall Score

BBIO MarketRank™: 

BridgeBio Pharma scored higher than 92% of companies evaluated by MarketBeat, and ranked 111th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BridgeBio Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    BridgeBio Pharma has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about BridgeBio Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for BridgeBio Pharma are expected to decrease in the coming year, from ($2.58) to ($3.52) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BridgeBio Pharma is -9.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BridgeBio Pharma is -9.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about BridgeBio Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    11.71% of the float of BridgeBio Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    BridgeBio Pharma has a short interest ratio ("days to cover") of 8.8.
  • Change versus previous month

    Short interest in BridgeBio Pharma has recently decreased by 3.26%, indicating that investor sentiment is improving.
  • Dividend Yield

    BridgeBio Pharma does not currently pay a dividend.

  • Dividend Growth

    BridgeBio Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.71% of the float of BridgeBio Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    BridgeBio Pharma has a short interest ratio ("days to cover") of 8.8.
  • Change versus previous month

    Short interest in BridgeBio Pharma has recently decreased by 3.26%, indicating that investor sentiment is improving.
  • News Sentiment

    BridgeBio Pharma has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 32 news articles for BridgeBio Pharma this week, compared to 7 articles on an average week.
  • Search Interest

    12 people have searched for BBIO on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added BridgeBio Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BridgeBio Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $150,056,923.00 in company stock.

  • Percentage Held by Insiders

    24.66% of the stock of BridgeBio Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    99.85% of the stock of BridgeBio Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about BridgeBio Pharma's insider trading history.
Receive BBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter.

BBIO Stock News Headlines

BridgeBio Pharma (BBIO) Gets a Buy from Scotiabank
This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
Equities Analysts Offer Predictions for BBIO FY2024 Earnings
BridgeBio reports open-label extension data on acoramidis in ATTR-CM
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $45.00 at Scotiabank
See More Headlines

BBIO Stock Analysis - Frequently Asked Questions

BridgeBio Pharma's stock was trading at $40.37 at the beginning of the year. Since then, BBIO stock has decreased by 42.9% and is now trading at $23.04.
View the best growth stocks for 2024 here
.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) released its quarterly earnings results on Thursday, August, 1st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.61. BridgeBio Pharma's revenue was up 32.1% on a year-over-year basis.

BridgeBio Pharma (BBIO) raised $225 million in an IPO on Thursday, June 27th 2019. The company issued 15,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR acted as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.

Top institutional shareholders of BridgeBio Pharma include Janus Henderson Group PLC (2.55%), Frazier Life Sciences Management L.P. (1.99%), Geode Capital Management LLC (1.81%) and The Manufacturers Life Insurance Company (0.81%). Insiders that own company stock include Genetic Disorder LP Kkr, Global Investors Lp Viking, Neil Kumar, Frank Mccormick, Brian C Stephenson, Randal W Scott, Hannah Valantine, Ronald J Daniels and Douglas A Dachille.
View institutional ownership trends
.

Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that BridgeBio Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW).

Company Calendar

Last Earnings
8/01/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/27/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BBIO
Fax
N/A
Employees
400
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$47.57
High Stock Price Target
$70.00
Low Stock Price Target
$37.00
Potential Upside/Downside
+106.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

Net Income
$-643,200,000.00
Net Margins
-201.53%
Pretax Margin
-204.94%

Debt

Sales & Book Value

Annual Sales
$9.30 million
Book Value
($7.72) per share

Miscellaneous

Free Float
142,385,000
Market Cap
$4.35 billion
Optionable
Optionable
Beta
1.09
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:BBIO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners